OKYO Profile
OKYO Pharma Limited, headquartered in London, United Kingdom, is a pioneering biopharmaceutical firm dedicated to advancing therapeutic solutions for patients afflicted with inflammatory eye diseases and ocular pain. Founded in 2007, the company specializes in preclinical research and development, focusing on innovative treatments designed to address significant unmet medical needs within the ophthalmology sector.
At the forefront of OKYO Pharma's pipeline is OK-101, its lead product targeting the treatment of dry eye disease. Leveraging cutting-edge scientific methodologies, OK-101 aims to alleviate symptoms and improve quality of life for patients suffering from this prevalent ocular condition. Additionally, the company is advancing OK-201, a preclinical candidate derived from bovine adrenal medulla and lipidated-peptide analogues, specifically designed to address neuropathic ocular pain, further underscoring OKYO Pharma's commitment to therapeutic innovation.
OKYO Pharma's strategic approach integrates rigorous preclinical research with a focus on advancing candidates through clinical development stages. By collaborating with leading academic institutions and leveraging partnerships with industry experts, the company accelerates its discovery process and enhances the potential for therapeutic breakthroughs. Furthermore, OKYO Pharma maintains a robust intellectual property portfolio, safeguarding its innovative technologies and reinforcing its competitive position in the biopharmaceutical landscape.
As OKYO Pharma continues to expand its research capabilities and therapeutic portfolio, it remains dedicated to achieving regulatory milestones and commercializing novel treatments that offer meaningful clinical benefits. With a steadfast commitment to scientific excellence and patient-centered innovation, OKYO Pharma is poised to redefine standards of care in ophthalmic medicine, addressing critical healthcare challenges and improving outcomes for patients worldwide.
|
